- Levitee Labs (LVT) has appointed a medical advisory board with decades of expertise in addiction and mental health disorders
- Fields of expertise include addiction, mental health, drug development, compounding, chronic pain, policy, neurology, and psychedelics
- The formation of the advisory board aligns with Levitee Labs agreements to acquire addiction-focused clinics and pharmacies in Alberta and British Columbia
- The establishment of this advisory board will help Levitee establish itself as the leading national provider of comprehensive mental health and addiction treatments
- Labs Inc. (LVT) is down on the day, trading at C$0.26 at 11:34 am EST
Levitee Labs (LVT) has formed a medical advisory board of experts with a diverse range of expertise in addiction and mental health disorders.
Fields of expertise include addiction, mental health, drug development, compounding, chronic pain, policy, neurology, and psychedelics.
The establishment of this advisory board will help Levitee Labs establish itself as the leading national provider of comprehensive mental health and addiction treatments.
North Americans are faced with ever-increasing mental health and addiction disorders that demand innovation to flatten and reverse the curve.
Canada suffered a 74 per cent increase in opioid-related deaths over the course of the first six months of the COVID-19 pandemic.
To be effective, today’s standard of care must provide appropriate treatments and address the additional health issues that come with addiction and mental health disorders.
Levitee Labs is deeply committed to providing specialized mental health support to those in need through a strategy that includes consolidating and optimizing clinics and pharmacies and developing new treatment options, including those leveraging active ingredients in psychedelics.
Levitee Labs recruited each member of its new medical advisory board for their individual expertise and cumulative synergies that will facilitate growth through connection to other thought leaders and major players in all relevant industries.
“I’d like to formally welcome each new Medical Advisor; we are honoured to have you as part of our team,” commented Pouya Farmand, Chief Executive Officer at Levitee Labs.
“Our strategy is solid, and our team is unparalleled, a combination that points to a bright future where negative addiction stigmas are removed and instead of feeling hopeless, patients readily get the help and support they need to overcome their difficult disorders,” added Farmand.
The Levitee Labs Medical Advisory Board consists of Mark Tarnopolsky, MD, Ph.D., FRCP(C), Noha ElSayed, B.Sc.Pharm, APA, Bakir Al Tikriti, MD M.B.ch.B CCFP PGC(PAIN), Mohammed Mosli, MD, FRCPC, ISAM, and Eding Mvilongo, MD.
Levitee is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.
Labs Inc. (LVT) is down on the day, trading at C$0.26 at 11:34 am EST.
